Drugs / Liposomal Vincristine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02518750 | Nov 2016 → Mar 2018 | T-cell leukemia, acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00038207 | Jun 2000 → Sep 2004 | Wilms tumor, leukemia, lymphoma, osteosarcoma +1 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01478542 | Nov 2011 → Jan 2024 | aggressive B-cell non-Hodgkin lymphoma | Saarland University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Liposomal vincristine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02518750 ↗ |
| Route | Intravenous | “administered via a central venous catheter” NCT00038207 ↗ |